ChainCatcher report, according to PRNewswire, Nasdaq-listed Canton Strategic Holdings announced the completion of the sale of its biotechnology R&D division, Gravitas Life Sciences, to Gravitas Collective Corp. The transaction was unanimously approved by the company’s board of directors and officially closed on July 17, 2026. This sale marks a further step in the company’s transformation into an operational enterprise focused on digitizing traditional financial markets through Canton Network, advancing asset tokenization, financial market digitization, and financial infrastructure services.
Canton Strategic Sells Gravitas Life Sciences to Focus on Financial Market Digitization
ChaincatcherShare
Summary
Canton Strategic Holdings, a NASDAQ-listed company, has sold its biotech R&D division, Gravitas Life Sciences, to Gravitas Collective Corp. The board-approved transaction closed on July 17, 2026. This move supports the company’s strategic shift toward financial market digitization through the Canton Network. On-chain updates underscore the transition toward asset tokenization and financial infrastructure. Market reports indicate that Canton is now focused on developing a digital financial services platform.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.